發(fā)布時(shí)間：2021-03-06 04:24

　　AIM:To investigate the mechanism and in vivo effects of MK-0626,a dipeptidyl peptidase-4 inhibitor,on hepatic steatosis using ob/ob mice.METHODS:We analyzed obese（ob/ob）8-wk-old male mice that had been randomly divided into two groups of ob/ob mice（n=16 each）and were treated with1.5 or 3 mg/kg MK-0626 and two control groups of untreated ob/ob mice and lean littermates（n=16 each）.All mice were fed a normal chow diet with or without MK-0626 for either four or eight weeks.Blood samples were collect... 

【文章來(lái)源】：World Journal of Gastroenterology. 2014,20(43)

【文章頁(yè)數(shù)】：9 頁(yè)

【文章目錄】：
INTRODUCTION
MATERIALS AND METHODS
    Animals, treatment and specimen collection
    Hepatic lipid profiles
    Biochemical and histological analysis
    RNA expression analysis of the liver specimen
    Western blotting analysis
    Statistical analysis
RESULTS
    MK-0626 treatment increased active GLP-1concentrations in the serum of ob/ob mice compared to MK-0626-untreated ob/ob mice
    MK-0626 treatment did not significantly change body weight, food intake or the ratio of liver weight to body weight in ob/ob mice
    MK-0626 treatment reduced hepatic fat content in ob/ob mice
    MK-0626 treatment increased PPARαand MTP m RNA expression and decreased the m RNA expression of SREBP-1c, SCD-1 and FAS
    MK-0626 treatment increased AMPK activation in whole liver in a dose-dependent manner
DISCUSSION
COMMENTS
    Background
    Research frontiers
    Innovations and breakthroughs
    Peer review



本文編號(hào)：3066432